Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 158

1.

Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316).

Deutsch GB, Deneve JL, Al-Kasspooles MF, Nfonsam VN, Gunderson CC, Secord AA, Rodgers P, Hendren S, Silberfein EJ, Grant M, Sloan J, Sun V, Arnold KB, Anderson GL, Krouse RS.

Am J Hosp Palliat Care. 2019 May 23:1049909119851471. doi: 10.1177/1049909119851471. [Epub ahead of print]

PMID:
31122027
2.

Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma.

Veade AE, Foote J, Ehrisman J, Broadwater G, Davidson BA, Lee PS, Secord AA, Berchuck A, Havrilesky LJ.

World J Surg Oncol. 2019 May 10;17(1):80. doi: 10.1186/s12957-019-1620-x.

3.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
4.

Ovarian cancer: time to move beyond one size fits all.

Secord AA.

Lancet Oncol. 2019 Jun;20(6):754-755. doi: 10.1016/S1470-2045(19)30285-2. Epub 2019 May 7. No abstract available.

PMID:
31076364
5.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.

Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30948273
6.

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.

Secord AA, McCollum M, Davidson BA, Broadwater G, Squatrito R, Havrilesky LJ, Gabel AC, Starr MD, Brady JC, Nixon AB, Duska LR.

Gynecol Oncol. 2019 Jun;153(3):555-561. doi: 10.1016/j.ygyno.2019.03.246. Epub 2019 Mar 28.

PMID:
30929823
7.

Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.

Foote JR, Secord AA, Liang MI, Ehrisman JA, Cohn DE, Jewell E, Havrilesky LJ.

Gynecol Oncol. 2019 Mar;152(3):445-451. doi: 10.1016/j.ygyno.2018.11.028.

PMID:
30876487
8.

U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.

Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ.

Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.

PMID:
30870286
9.

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.

Lim SL, Havrilesky LJ, Habib AS, Secord AA.

Gynecol Oncol. 2019 May;153(2):376-380. doi: 10.1016/j.ygyno.2019.01.025. Epub 2019 Feb 1.

PMID:
30718126
10.

Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management.

Previs RA, Secord AA.

Obstet Gynecol Clin North Am. 2019 Mar;46(1):67-88. doi: 10.1016/j.ogc.2018.09.005. Review.

PMID:
30683267
11.

Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Moore K, Chan JK, Secord AA, Patel MR, Callahan T, Guo W, Zhang ZY.

Cancer Chemother Pharmacol. 2019 Apr;83(4):717-726. doi: 10.1007/s00280-019-03774-w. Epub 2019 Jan 24.

PMID:
30680521
12.

The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.

Puechl AM, Edwards J, Suri A, Nakayama J, Bean S, Gehrig P, Saks E, Duska L, Broadwater G, Ehrisman J, Horowitz N, Secord AA.

Gynecol Oncol. 2019 Apr;153(1):74-79. doi: 10.1016/j.ygyno.2019.01.016. Epub 2019 Jan 18.

PMID:
30661765
13.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ.

Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum in: Obstet Gynecol. 2019 Apr;133(4):830.

PMID:
30633128
14.

Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.

Davidson BA, Broadwater G, Crim A, Boccacio R, Bixel K, Backes F, Previs RA, Salinaro J, Salani R, Moore K, Secord AA.

Gynecol Oncol. 2019 Mar;152(3):554-559. doi: 10.1016/j.ygyno.2018.12.011. Epub 2018 Dec 14.

PMID:
30558972
15.

Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy.

Dotson S, Landa A, Ehrisman J, Secord AA.

Gynecol Oncol Res Pract. 2018 Oct 30;5:8. doi: 10.1186/s40661-018-0065-1. eCollection 2018.

16.

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.

Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H.

Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001.

17.

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian C.

Gynecol Oncol. 2018 Dec;151(3):422-427. doi: 10.1016/j.ygyno.2018.10.001. Epub 2018 Oct 8.

PMID:
30309721
18.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

19.

Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis.

Lim SL, Moss HA, Secord AA, Lee PS, Havrilesky LJ, Davidson BA.

Gynecol Oncol. 2018 Dec;151(3):506-512. doi: 10.1016/j.ygyno.2018.09.020. Epub 2018 Sep 23.

PMID:
30257786
20.

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.

Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA.

Gynecol Oncol. 2018 Nov;151(2):257-263. doi: 10.1016/j.ygyno.2018.08.027. Epub 2018 Aug 31.

PMID:
30177462

Supplemental Content

Loading ...
Support Center